IRIS, HLH and persistent TB in a patient with HIV
Transactions of The Royal Society of Tropical Medicine and Hygiene · 07.07.2026 · 120 (7) · 812-817
DOI: 10.1093/trstmh/trag040 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transactions of The Royal Society of Tropical Medicine and Hygiene, online erschienen am 24.04.2026. Verfasst von Praveen Kumar Tirlangi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka 576104, India. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Immune Reconstitution Inflammatory Syndrome, HIV Infections, Tuberculosis. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Immune reconstitution inflammatory syndrome (IRIS) is a frequent complication of advanced human immunodeficiency syndrome (HIV)–tuberculosis (TB) coinfection and, in severe cases, may overlap with secondary haemophagocytic lymphohistiocytosis (HLH), creating significant diagnostic and therapeutic uncertainty. We report a 34-year-old man with newly diagnosed HIV infection (CD4 count 54 cells/mm3) who developed disseminated TB 2 weeks after initiation of antiretroviral therapy, consistent with unmasking TB-associated IRIS. Despite appropriate antitubercular therapy (ATT) and corticosteroids, he developed persistent fever, progressive cytopenias, hyperferritinaemia and bone marrow haemophagocytosis, fulfilling criteria for secondary HLH, with transient clinical improvement following etoposide therapy. During corticosteroid tapering, recurrent fever occurred with persistent splenic lesions despite radiologic resolution of pulmonary disease. Splenectomy demonstrated necrotizing granulomatous inflammation with a heavy acid-fast bacillary load, confirming a microbiologically active splenic sanctuary focus. Subsequent therapeutic drug monitoring revealed markedly subtherapeutic rifampicin and ethambutol concentrations, prompting dose escalation and optimization of ATT. Following antimicrobial optimization and gradual withdrawal of immunosuppression, the patient achieved sustained clinical recovery, virologic suppression and immune reconstitution. This case illustrates a sequential continuum linking TB-IRIS, secondary HLH and infection-sustained inflammation driven by inadequate antimicrobial exposure, emphasizing the importance of reassessing persistent inflammation in HIV-TB for occult infection and pharmacokinetic failure before escalation of immunosuppressive therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka 576104, India.
ORCID-Profile: Praveen Kumar Tirlangi, Venkata Swathi Kiran Pothumarthy, Anjely Sebastian, Nitin Gupta
Zitieren
APA
Tirlangi, P. K., Pothumarthy, V. S. K., Sebastian, A., & Gupta, N. (2026). IRIS, HLH and persistent TB in a patient with HIV. Transactions of The Royal Society of Tropical Medicine and Hygiene, 120(7), 812-817. https://doi.org/10.1093/trstmh/trag040
Vancouver
Tirlangi PK, Pothumarthy VSK, Sebastian A, Gupta N. IRIS, HLH and persistent TB in a patient with HIV. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2026;120(7):812-817. doi:10.1093/trstmh/trag040
BibTeX
@article{Tirlangi2026,
author = {Tirlangi, Praveen Kumar and Pothumarthy, Venkata Swathi Kiran and Sebastian, Anjely and Gupta, Nitin},
title = {IRIS, HLH and persistent TB in a patient with HIV},
journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
year = {2026},
volume = {120},
number = {7},
pages = {812--817},
doi = {10.1093/trstmh/trag040}
}
EUVIMED